Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 6/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5486895 | 0.91 | GRIA2 (0.49) | GRIA2TDP1L3MBTL1 | |
| SCHEMBL5477040 | 0.86 | GRIA2 (0.39) | GRIA2KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5483529 | 0.82 | GRIA2 (0.41) | GRIA2 | |
| SCHEMBL5484644 | 0.79 | GRIA2 (0.40) | GRIA2POLB | |
| SCHEMBL5479492 | 0.77 | GRIA2 (0.38) | GRIA2 | |
| SCHEMBL5477044 | 0.76 | GRIA2 (0.49) | GRIA2POLB | |
| SCHEMBL5479485 | 0.75 | GRIA2 (0.38) | GRIA2L3MBTL1KMT2A | |
| SCHEMBL5476903 | 0.74 | GRIA2 (0.51) | GRIA2 | |
| SCHEMBL5481538 | 0.74 | GRIA2 (0.72) | GRIA2SMN1; SMN2 | |
| SCHEMBL5482327 | 0.73 | GRIA2 (0.39) | GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1655030-B1 | Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same | SERVIER LAB (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20070270415-A1 | Benzothiadiazine compounds | LESLABORATOIRES SERVIER (FR) | 2007-11-22 | — | — | US | disclosed |
| US-7268130-B2 | Benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2007-09-11 | — | — | US | disclosed |
| EP-1655030-A1 | Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same | Les Laboratoires Servier (FR) | 2006-05-10 | — | — | EP | disclosed |
| US-20060094712-A1 | New benzothiadiazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270415-A1 | Benzothiadiazine compounds | SLC1A1, SLC1A2, SULT2A1 | GRIA2 47/4885MMP13 4800/4885TDP1 1417/4885 |
| US-20060094712-A1 | New benzothiadiazine compounds | SLC1A1, SLC1A2, GABRA5 | GRIA2 36/4885MMP13 4813/4885TDP1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.